jeudi 30 juin 2016

Onco Actu du 30 juin 2016

3. Prévention

Following prevention guidelines linked to lowered risk for cancer [Reuters]

3.3 Prévention - Vaccins

Merck holds parents accountable in new Gardasil ad campaign [FiercePharma]

4. Dépistage, diagnostic et pronostic

Tailored health campaigns could help ethnic groups spot cancer symptoms earlier [Cancer Research UK]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Cancer Genetics, Inc. Expands Its Immuno-Oncology Franchise With The Addition of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ™ [Cancer Genetics]

5. Traitements

Leukaemia drug shows potential for rarer type of ovarian cancer [The Institute of Cancer Research]

5.10 Traitements - Essais

Myriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib [Myriad]

PARP Inhibitors Come Through [In the Pipeline]

Tesaro Shares Surge 82% Because Drug Slows Ovarian Cancer [Forbes]

Tesaro's ovarian cancer drug shows benefit in late-stage trial [Reuters]

5.12 Immunothérapies

EORTC literature review highlights methodology issues in immuno oncology [EORTC]

World GI 2016 Press Release: Anti-PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination with MEK Inhibition [ESMO]

5.2 Pharma

AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options [AbbVie]

5.2.1 Pharma - Partenariats

Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact [Xconomy]

5.2.2 Pharma - Fusions & Acquisitions

What Tesaro's Cancer Drug Success Means for Medivation [The Street]

5.2.3 Pharma - économie

Syros Cuts Price But Gets $50M in IPO to Fuel Cancer Drug Trials [Xconomy]

5.3 Traitements - FDA, EMA,...

FDA issues new draft guidelines for ‘appearance’ of conflicts of interest [STAT]

US FDA Advisory Subcommittee Weighs in on Pediatric Oncology Candidates and Discusses Treatment Approaches for Fatal Pediatric Brain Tumor – JUN 28-29, 2016 [SAC Tracker]

5.4 Traitements - Economie

Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Cancer” [BMS]

6. Lutte contre les cancers

Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century [The National Academies Press]

Interdisciplinary proposals struggle to get funded [Nature News & Comment]

6.1 Observation

Heart disease and cancer are responsible for nearly half of all deaths in the U.S., report says [LA Times]

6.10.1 Politiques (USA)

American Society of Hematology Data Sharing Initiative to Be Featured at National Cancer Moonshot Summit Today [ASH]

Significant expansion of data available in the Genomic Data Commons [NIH]

Our Moonshot pledge to accelerate research on detecting early signs of cancer [Cancer Research UK]

Statement from FDA Commissioner Robert Califf, M.D. announcing the acting director of the FDA Oncology Center of Excellence [FDA]

Foundation Medicine On Biden's Cancer Moonshot: A 'Pep Rally' Can't Hurt [Forbes]

Biden to unveil effort to speed researchers’ access to cancer drugs [STAT]

Biden threatens funding cuts for researchers who fail to report clinical trial results [STAT]

The Cancer Moonshot Summit: A Day For Our Nation To Reflect And Commit To What We Can Accomplish To Make This Cancer’s Last Century [Dr. Len's Blog]

FDA names Pazdur head of new Oncology Center of Excellence [Reuters]

The Rocket Fuel for Biden’s “Cancer Moonshot”? Big Data [MIT Technology Review]

6.11 Patients

Simple questions predict decline after breast cancer treatment [Reuters]

6.6 Publications

ArXiv preprint server plans multimillion-dollar overhaul [Nature News & Comment]

6.9 Controverses

U.S. should abandon controversial effort to update human research rules, National Academies panel says [Science]

Science academies blast US government’s planned research-ethics reforms [Nature News & Comment]